Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

Autor: Despierre, Evelyn, Vergote, Ignace, Anderson, Ryan, Coens, Corneel, Katsaros, Dionyssios, Hirsch, Fred R., Boeckx, Bram, Varella Garcia, Marileila, Ferrero, Annamaria, Ray Coquard, Isabelle, Berns, Els M. J. J., Casado, Antonio, Lambrechts, Diether, Jimeno, Antonio, Abraham, C, Chesnay, L, Amant, F, Anderson, R, Azzedine, A, Benedetto, Chiara, Bertelli, G, Berteloot, P, Berton Rigaud, D, Biglia, N, Bonichon Lamichhane, N, Bougnoux, P, Bourbouloux, E, Bourcier, C, Buck, M, Campone, M, Canuto, Em, Casado Herraez, A, Cauvin, I, Chauvenet, L, Chevalier Place, A, Cottu, P., Cretin, J, Cumin, I, Curé, H, Dalenc, F, Danese, S, Davis, A, Debruyne, P, Delplanque, G, Delva, R, D'Hondt, V, Dramais, D, Durando, X, El Kouri, C, Esteban, C, Fabbro, M, Falandry, C, Filleul, B, Floquet, A, Fumoleau, P, Garcia Varella, M, Garnier, C, Gilby, E, Gladieff, L, Goffin, F, Gouttebel, M., Green, Ja, Guastalla, J., Hardy Bessard, A., Hirsch, F, Hughes, A, Jaubert, D, Kaminsky, M., Katsaros, D, Largillier, R, Lebrun Jezekova, D, Leduc, B, Leheurteur, M, Lesoin, A, Leunen, K, Levasseur, N, Leyronnas, C, Llory, J., Lortholary, A, Mayer, F, Mayeur, D, Mendiola, C, Mignot, L, Morgan, J, Mouret Reynier, M., Neven, P, Petit, T, Picardo, E, Plaza, J, Pluvio Coronado, M, Priou, F, Pujade Lauraine, E, Coquard, I, Reed, N, Rigault de la Longrais, I, Scholl, S, Sillet Bach, I, Steer, C, Summers, J, Trillet Lenoir, V, Van Dam, P, Van Der Burg ME, Vanlerenberghe, E, Vannetzel, J., Vergote, I, Aragon, Ja, Waters, J, Weber, B, Yazbek, G, Zola, P.

Publikováno v: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Targeted Oncology, 10(4), 583-596. Springer Paris
Targeted oncology, 10(4), 583-596. Springer Paris

In this work, we aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in patients with ovarian cancer who were treated within the phase III randomized European Organisation for Research and Treatment of Cancer-Gynaeco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afac208980ec6c8a006dd3896a3078de
https://doi.org/10.1007/s11523-015-0369-6

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

Autor: Vergote, I, Tropé, Cg, Amant, F, Kristensen, Gb, Ehlen, T, Johnson, N, Verheijen, Rh, van der Burg ME, Lacave, Aj, Panici, Pb, Kenter, Gg, Casado, A, Mendiola, C, Coens, C, Verleye, L, Stuart, Gc, Pecorelli, S, Reed, Ns, Angioli, R, Bentley, J, Berteloot, P, Bessette, P, Boman, K, Buist, M, Chan, K, Chan, S, Coronado Martín, P, Counsell, R, Cruickshank, Dj, Davis, J, De Greve, J, De Oliveira CF, De Valk, B, Dittrich, C, Elit, L, Favalli, G, Floquet, A, Gauthier, P, Gerdin, E, Ghatage, P, Gilby, E, Gleeson, N, Gotlieb, W, Green, Ja, Grimshaw, R, Heywood, M, Hirsch, V, Hoekman, K, Honkoop, A, Hoskins, P, Kannisto, P, Kaern, J, Katsaros, D, Kieser, K, Kristeller, Tv, Leblanc, E, Ledermann, J, Leunen, K, Lotocki, R, Maggino, T, Marth, C, Martin, L, Massuger, L, Miller, D, Mosgaard, B, Mota, F, Neven, P, Nooij, M, Nordal, R, Nordin, A, Ottevanger, Pb, Papadopoulos, A, Petru, E, Plante, M, Popadiuk, C, Provencher, D, Redman, C, Roozendaal, Kj, Rustin, G, Sadozye, Ah, Sandvei, R, Seoane, Jm, Sereni, Mi, Sert, B, Siddiqui, N, Speiser, P, Tholander, B, Tognon, G, Trimbos, B, Trudeau, M, Van Baal, M, Van Doorn HC, Van der Velden, J, Van Eygen, K, Vermorken, Jb, Vidart Aragon JA, Wensveen, Cw, Zola, Paolo, Anastosopoulou, A, Bethe, U, Dehaes, K, Demeester, A, Demonty, G, De Heusch, E, De Rouck, M, Giurgea, L, Hoctin Boes, G, Teodorovic, I, Ven, K, Van Luijk, I, Bacon, M, Eisenhauer, E.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______970::7c662085eb897b59c1871a9aab8f2474
http://hdl.handle.net/2318/80625

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Autor: Aapro, Ms, VAN WIJK FH, Bolis, G, Chevallier, B, VAN DER BURG ME, Poveda, A, Oliveira, Cf, Tumolo, S, SCOTTO DI PALUMBO, V, Piccart, M, Franchi, M, Zanaboni, F, Lacave, Aj, Fontanelli, R, Favalli, G, Zola, Paolo, Guastalla, Jp, Rosso, R, Marth, C, Nooij, M, Presti, M, Scarabelli, C, Splinter, Ta, Ploch, E, Beex, Lv, Ten, Bokkel, Huinink, W, Forni, M, Melpignano, M, Blake, P, Kerbrat, P, Mendiola, C, Cervantes, A, Goupil, A, Harper, Pg, Madronal, C, Namer, M, Scarfone, G, Stoot, Je, Teodorovic, I, Coens, C, Vergote, I, Vermorken, Jb

Publikováno v: Annals of Oncology, 14(3), 441-448. Oxford University Press
Annals of Oncology, 14, 441-448. Elsevier Ltd.

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Background: Combination chemotherapy yields better response rates which do not always le

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70b40711f56da0752147ed7ef101ed61
http://hdl.handle.net/11562/302635

Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study

Autor: Vermorken, JB, Zanetta, G, Oliveira, CF, Van der Burg, ME, Lacave, AJ, Teodorovic, I

PURPOSE: Three previous mitomycin-cisplatin-based chemotherapy trials conducted within the EORTC Gynecological Cancer Cooperative Group (GCCG) in patients with disseminated squamous-cell carcinoma of the uterine cervix (SCCUC) suggested that with suc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1504::0294aebad1bf1c6d0af1a02c46fce283
https://hdl.handle.net/10400.4/121

A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance

Autor: van der Burg Me, R. Oosterom, H. Herweijer, A. S. T. Planting, Jaap Verweij, Caroline Seynaeve, Gerrit Stoter, Kees Nooter

Publikováno v: British Journal of Cancer

We determined the ability of the multidrug resistance (MDR) reversal agent cyclosporin-A to increase anthracycline drug accumulation in colorectal tumour cells in vitro, using the technique of on-line flow cytometry. Data of four previously untreated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d283ade9b64776e1fcf256339fc44c68
https://pubmed.ncbi.nlm.nih.gov/1892765